Bile Duct Tumors Medication

Updated: Apr 20, 2020
  • Author: Todd A Nickloes, DO, FACOS; Chief Editor: John Geibel, MD, MSc, DSc, AGAF  more...
  • Print
Medication

Medication Summary

Few patients are diagnosed with early-stage resectable tumors. Guidelinesfor unresectable or metastatic disease include various chemotherapy regimens. [22]

In April 2020, the FDA approved pemigatinib, the first targeted therapy for cholangiocarcinoma with FGFR2 fusion or rearrangement.

Next:

FGFR Inhibitors

Class Summary

Inhibition of FGFR disrupts tumor cell proliferation, survival, migration, and angiogenesis.

Pemigatinib (Pemazyre)

Pemigatinib is a small molecule kinase inhibitor that targets FGFR1, 2, and 3 by inhibiting FGFR1-3 phosphorylation and signaling. Indicated for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. 

Previous